Key highlights
- Cash runway extended into 2029, a one-year improvement over previous management guidance
- XmAb819 Phase 1 results support a potential registration-enabling study start in 2027
- Year-end 2026 cash and marketable securities projected between $420 million and $440 million
- Candidate targets ENPP3, a protein highly expressed in clear cell renal cell carcinoma
- Xencor maintains 100% ownership of the XmAb819 program and its 2+1 T-cell engager platform
Phase 1 Clinical Advancements
Xencor disclosed updated data from its Phase 1 dose expansion study of XmAb819, a bispecific T-cell engager targeting ENPP3 and CD3. The trial focused on patients with advanced clear cell renal cell carcinoma (ccRCC), a population with significant unmet need. The updated results, presented at the ESMO 2026 conference, provide the clinical foundation for a registration-enabling study scheduled to commence in 2027. By utilizing the proprietary XmAb 2+1 platform, the candidate is designed to improve the therapeutic index by enhancing tumor selectivity and reducing off-target effects, a common challenge for T-cell engaging therapies in solid tumors.
Operational and Financial Strength
In conjunction with the clinical update, Xencor revised its financial guidance, now projecting a cash runway that extends into 2029. This extension provides nearly three years of additional operational funding compared to earlier 2026 forecasts. The improved outlook is supported by a stable balance sheet and recent non-dilutive capital inflows, including a $105 million settlement with Alexion over Ultomiris royalties. Management expects to finish 2026 with approximately $420 million to $440 million in cash and marketable debt securities, ensuring the company can advance its wholly owned oncology pipeline without the immediate pressure of secondary equity offerings.
Up 40.6% since our story on 26 Oct: $25.18 when we broke it → $35.40 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $23.19 |
|---|---|
| 20 Oct | $24.94 |
| 21 Oct | $25.16 |
| 22 Oct | $25.84 |
| 23 Oct | $25.18 |
| 26 Oct | $29.18 |
| 27 Oct | $29.99 |
| 28 Oct | $29.99 |
| 29 Oct | $29.21 |
| 30 Oct | $29.82 |
| 2 Nov | $29.66 |
| 3 Nov | $30.64 |
| 4 Nov | $35.03 |
| 5 Nov | $34.05 |
| 6 Nov | $35.75 |
| 9 Nov | $38.59 |
| 10 Nov | $39.39 |
| 11 Nov | $39.97 |
| 12 Nov | $38.13 |
| 13 Nov | $37.09 |
| 16 Nov | $35.40 |
Strategic Development Pipeline
- XmAb819 remains a 100% wholly owned asset, preserving full commercial rights for Xencor
- The 2027 registrational study goal marks a transition to late-stage clinical development for the program
- Platform focus remains on bispecific T-cell engagers for solid tumors and autoimmune conditions
- Ongoing collaborations provide a steady stream of royalty revenue and milestone potential
- Company targets a lean operational model to maximize R&D investment through the 2029 runway
Biotechnology Sector Context
The oncology landscape is increasingly shifting toward bispecific antibodies and T-cell engagers as validated alternatives to traditional checkpoint inhibitors. Xencor occupies a specialized niche within this sector by focusing on protein engineering to optimize antibody half-life and target binding. While the clear cell renal cell carcinoma market is competitive, the unique targeting of ENPP3 differentiates XmAb819 from other agents in development. As the company moves toward potential accelerated approval pathways in 2027, its financial stability into 2029 offers a rare level of visibility in the mid-cap biotechnology space.
| Date | Announcement | Amount |
|---|---|---|
| 25 Oct 2026 | Presented Phase 1 dose selection data for XmAb819 at ESMO 2026Source: biospace.com | – |
| 05 Aug 2026 | Reported second quarter 2026 financial resultsSource: SEC filing | – |
| 29 Jul 2026 | Reached settlement agreement with Alexion over Ultomiris U.S. royaltiesSource: SEC filing | $105.0 Million |
| 17 Jul 2026 | Announced proffered paper oral presentation at ESMO 2026 for Phase 1 study of XmAb819Source: investors.xencor.com | – |
| 06 May 2026 | Reported first quarter 2026 financial resultsSource: investors.xencor.com | – |
| 04 Mar 2026 | Announced change to Ultomiris royalty revenue forecast following dispute notice from AlexionSource: SEC filing | – |
| Share price | $25.18 |
|---|---|
| Market cap | $1.9B |
| Revenue (annual) | $126M |
| 1-month price change | +3.79% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Xencor, Inc. announcing updated results from its Phase 1 study of XmAb819 and an updated cash runway through 2029.
Track Xencor Inc live
Get the next Xencor Inc SEC filing seconds after it lands.